CYMD 201
Alternative Names: CYMD-201Latest Information Update: 28 Nov 2024
At a glance
- Originator FibroGenesis
- Class Gene therapies
- Mechanism of Action Dystrophin expression stimulants; Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Duchenne muscular dystrophy; Muscular dystrophies
Most Recent Events
- 28 Nov 2024 No recent reports of development identified for preclinical development in Duchenne muscular dystrophy in USA (Parenteral)
- 28 Nov 2024 No recent reports of development identified for preclinical development in Muscular-dystrophies in USA (Parenteral)
- 21 Oct 2020 FibroGenesis has patents pending for fibroblast based gene therapy for the treatment of Duchenne muscular dystrophy in USA (FibroGenesis' website, October 2020)